Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients

Alqahtani, Aayed R.; Al-Darwish, Abdullah; Mahmoud, Ahmed Elsayed; Alqahtani, Yara A; Elahmedi, Mohamed

doi:10.1016/j.gie.2018.12.012

Cited by 165 publications

(134 citation statements)

References 13 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…These first two observations possibly also explain our minimal loss to follow-up rate (2/ 53). Finally, our mean baseline BMI was 35, which was somewhat less than that of most other series 13,15,17,18 and similar to that of Alqahtani et al 19 and Barrichello et al 16 This fact highlights the role of ESG for mild rather than morbid obesity. A recent meta-analysis 20 reported a lower weight loss of 16% and a higher rate (77%) of mild adverse events; however, there were some methodological concerns with the study.…”

Section: Discussionsupporting

confidence: 81%

Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: First Indian experience

Bhandari

Jain

Mathur

et al. 2019

Digestive Endoscopy

View full text Add to dashboard Cite

Background and Aim: Endoscopic sleeve gastroplasty (ESG) is gaining acceptance as a non-surgical option for the treatment of obesity. However, its role is still not consolidated for all populations and the ideal indications are yet to be determined. We aimed to study the efficacy and safety of ESG in Indian patients. Methods:We conducted a single-center retrospective study of obese patients who underwent consecutive ESG at our tertiary care center. Data on weight loss and adverse events at 1, 3, 6, and 12 months were collected and analyzed. Results: Fifty-three patients underwent ESG from March 2017 toOctober 2018. Eighty one percent of patients were female (43/53). Mean baseline age and body mass index were 40.54 AE 13.79 years and 34.78AE 5.20 kg/m 2 , respectively. Mean duration of procedure was 68.96 AE 11.19 min. Immediate postoperative complications included mainly epigastric pain (45.2%) and nausea (22.6%) but there was no serious adverse event. Average percentage of total weight loss (%TWL) was 8.26%, 11.96%, 14.25%, and 19.94% at 1, 3, 6, and 12 months, respectively. Eighty-eight percent of patients achieved >15% TWL at 12 months. Younger patients (<30 years old) and female patients had greater %TWL at 12 months (P = 0.01 and P = 0.021, respectively). Last 18 procedures were significantly faster than the first 35 cases (P = 0.01).Conclusions: Endoscopic sleeve gastroplasty is effective and safe at promoting weight loss in the Indian population. Young age and female gender are related to better outcomes.

show abstract

Section: Discussionsupporting

confidence: 81%

Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: First Indian experience

Bhandari

Jain

Mathur

et al. 2019

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

“…1 Given these limitations, particularly in patients with lower body mass index (between 30 to 40 kg/m 2 ), endoscopic sleeve gastroplasty (ESG) is an attractive minimally invasive endoscopic alternative to surgery that expands the therapeutic benefits of effective obesity interventions targeting the GI tract to patients who do not qualify for or wish to pursue bariatric surgery. 2 In the largest series of patients undergoing ESG to date, Alqahtani et al 3 add to a growing body of literature that suggests ESG is ready for prime time in the evolving management paradigm of obesity and metabolic disease. In their first 1000 cases, the mean percentage of total body weight loss at 12 months was 15.0% AE 7.7%, with an SAE rate of <0.01, consistent with previously reported multicenter data.…”

mentioning

confidence: 99%

“…Perhaps the most critical information gleaned from the report by Alqahtani et al 3 stems from their very granular reporting of adverse events in these first 1000 cases. This information allows us to now set realistic expectations for the incidence and prevalence of SAE rates to be expected with ESG, particularly when combined with the international multicenter data now reported in the literature totaling 1607 unique cases.…”

mentioning

confidence: 99%

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Storm

Dayyeh

2019

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…ESG is now rapidly affirming as an effective alternative to LSG and there is initial evidence that it may be safer than LSG and effective in improving DM2, hypertension, reflux disease and obstructive sleep apnoea syndrome 28,29 . In the largest series described so far, including 1000 patients, ESG was well tolerated and effective in inducing significant weight loss without mortality or significant morbidity at 18‐month follow‐up 30 …”

Section: Endoscopic Sleeve Gastroplastymentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Salomone¹,

Sharaiha

Boškoski

2020

Liver International

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by noninvasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications. K E Y W O R D S bariatric endoscopy, duodenal mucosal resurfacing, endoscopic sleeve gastroplasty, intragastric balloon, NAFLD, obesity How to cite this article: Salomone F, Sharaiha RZ, Boškoski I. Endoscopic bariatric and metabolic therapies for nonalcoholic fatty liver disease: Evidence and perspectives. Liver

show abstract

Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients

Cited by 165 publications

References 13 publications

Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: First Indian experience

Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: First Indian experience

Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Contact Info

Product

Resources

About